Home/Filings/4/0001127602-23-004109
4//SEC Filing

Kirchgraber Paul R 4

Accession 0001127602-23-004109

CIK 0000920148other

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 12:02 PM ET

Size

7.9 KB

Accession

0001127602-23-004109

Insider Transaction Report

Form 4
Period: 2023-02-07
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
  • Award

    Non-qualified Stock Options

    2023-02-07+5,0005,000 total
    Exercise: $247.24From: 2024-02-07Exp: 2033-02-06Common Stock (5,000 underlying)
  • Award

    Restricted Stock Unit

    2023-02-07+1,5903,484 total
    Common Stock (1,590 underlying)
Footnotes (5)
  • [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
  • [F2]The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024.
  • [F3]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
  • [F4]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
  • [F5]The option vests in three equal annual installments beginning on the date reflected in this column.

Issuer

LABORATORY CORP OF AMERICA HOLDINGS

CIK 0000920148

Entity typeother

Related Parties

1
  • filerCIK 0001791393

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 12:02 PM ET
Size
7.9 KB